Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

Wolfgang Hiddemann; Anna Maria Barbui; Miguel A Canales; Paul K Cannell; Graham P Collins; Jan Duerig; Roswitha Forstpointner; Michael Herold; Mark Hertzberg; Magdalena Klanova; John Radford; John F Seymour; Kensei Tobinai; Judith Trotman; Alis Burciu; Gunter Fingerle-Rowson; Marcel Wolbers; Tina Nielsen; Robert E Marcus

Journal article

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

Wolfgang Hiddemann, Anna Maria Barbui, Miguel A Canales, Paul K Cannell, Graham P Collins, Jan Duerig, Roswitha Forstpointner, Michael Herold, Mark Hertzberg, Magdalena Klanova, John Radford, John F Seymour, Kensei Tobinai, Judith Trotman, Alis Burciu, Gunter Fingerle-Rowson, Marcel Wolbers, Tina Nielsen, Robert E Marcus

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2018

DOI: 10.1200/JCO.2017.76.8960

University of Melbourne Researchers

John Seymour Author Medicine - St Vincent's Hospital

Grants

Funding Acknowledgements

GALLIUM was sponsored by F. Hoffmann-La Roche. G.P.C. was supported by the Blood Theme of the Oxford National Institute for Health Research Biomedical Research Centre. Third-party medical writing assistance was funded by F. Hoffmann-La Roche.